PathTROL™ Connective 1 Control and PathTROL™ Connective 2 Control provide essential tools for the continuous quality control of connective tissue autoantibody testing in clinical laboratories. These controls ensure the accurate and reliable performance of your assays, allowing for confident and precise diagnosis of connective tissue disorders.

Connective tissue diseases (CTDs) encompass a range of multisystem conditions with overlapping clinical features, posing diagnostic challenges due to diverse symptoms. Early identification and specialist care are crucial to prevent organ damage and mortality. Although rare, CTDs vary in prevalence. Fatigue is a common nonspecific symptom, accompanied by additional manifestations like fevers, muscle and joint pain, weakness, and more. Explore each disease for concise symptom summaries.

Performing Connective Tissue Disease (CTD) and Symphony screening offers several key benefits in immunology diagnostic testing. Firstly, it allows for comprehensive evaluation and early detection of various autoimmune diseases, aiding in prompt diagnosis and appropriate management. By assessing a wide range of autoantibodies, it enhances the accuracy and specificity of disease identification. Additionally, CTD and Symphony screening help differentiate between different CTD subtypes, providing valuable insights for tailored treatment plans and improved patient outcomes. Overall, these screenings contribute to more effective and precise immunology diagnostics.

Connective Tissue Autoantibodies: The third-party controls consist of human serum containing human autoantibodies with specificities for a range of connective tissue antigens.

The PathTROL™ Connective 2 Control includes autoantibodies against the following specificities:

• dsDNA
• Centromere B (CENP-B)
• Scl-70
• Jo-1
• CTD Screen
• Symphony Screen

Ensure the accuracy and reliability of your connective tissue autoantibody testing with PathTROL™ Connective 1 Control and PathTROL™ Connective 2 Control. With specificities against a range of connective tissue antigens, convenient liquid formulation, and compliance with regulatory standards, these controls are essential tools for continuous quality control in connective tissue disorder diagnostics.